Manager × security

EMERALD ADVISERS, LLC TVTX holdings history

Who else holds this security? →

TRAVERE THERAPEUTICS INC · CUSIP 89422G107 · CIK 1015083

This is the oldest quarter open without an account, so changes against the quarter before it are withheld. Sign in to see them.
Citable facts

As of 2026-06-30, EMERALD ADVISERS, LLC reported 1.60M TVTX (shares), valued at $90.95M, or 2.14% of its reported non-derivative portfolio. Filed 2026-08-05.

Verify history & sources →
Portfolio weight and quantity history
Reported portfolio weight
2.14%
Shares
1.60M
1,600,886
Reported value
$90.95M
USD

Shares increased 2.81%; reported value increased 96.58%, and weight changed +0.68 pp. Weight depends on both the security valuation and total portfolio value, not trade proceeds.

Left: % · Right: Shares · Independently scaled axes

Exact data and methodology

Axes scale independently; a crossing does not mean equal values. Weight uses each quarter's total reported non-derivative value. Same CUSIP; missing quarters are gaps, not zero. Revised history may include later disclosures.

QuarterWeightQuantitySource
Q2 20262.14%1,600,886SEC filing ↗Filed Aug 5, 2026
Q1 20261.46%1,557,196SEC filing ↗Filed May 4, 2026
Q4 20251.88%1,594,184SEC filing ↗Filed Feb 9, 2026
Q3 20251.64%2,146,767SEC filing ↗Filed Oct 30, 2025
Q2 20251.13%2,091,360SEC filing ↗Filed Aug 4, 2025
Q1 20251.68%2,077,173SEC filing ↗Filed May 1, 2025
Q4 20241.43%2,125,744SEC filing ↗Filed Feb 11, 2025
Q3 20241.06%1,960,659SEC filing ↗Filed Oct 29, 2024
Q2 20240.56%1,637,146SEC filing ↗Filed Aug 6, 2024
Q1 20240.54%1,749,401SEC filing ↗Filed May 8, 2024
Q4 20230.40%1,046,149SEC filing ↗Filed Feb 5, 2024
Q3 20230.46%1,060,302SEC filing ↗Filed Oct 26, 2023

History & evidence by quarter

QuarterWeightQuantityValueChange explainedSource
Q3 20230.46%1,060,302$9.48MThe prior quarter is outside the free window. Sign in for the comparison.SEC filing ↗
Filed Oct 26, 2023
Q4 20230.40%1,046,149$9.40MShares decreased 1.33%; reported value decreased 0.78%, and weight changed -0.06 pp. Weight depends on both the security valuation and total portfolio value, not trade proceeds.SEC filing ↗
Filed Feb 5, 2024
Q1 20240.54%1,749,401$13.49MShares increased 67.22%; reported value increased 43.41%, and weight changed +0.14 pp. Weight depends on both the security valuation and total portfolio value, not trade proceeds.SEC filing ↗
Filed May 8, 2024
Q2 20240.56%1,637,146$13.46MShares decreased 6.42%; reported value decreased 0.23%, and weight changed +0.02 pp. Weight depends on both the security valuation and total portfolio value, not trade proceeds.SEC filing ↗
Filed Aug 6, 2024
Q3 20241.06%1,960,659$27.43MShares increased 19.76%; reported value increased 103.83%, and weight changed +0.50 pp. Weight depends on both the security valuation and total portfolio value, not trade proceeds.SEC filing ↗
Filed Oct 29, 2024
Q4 20241.43%2,125,744$37.03MShares increased 8.42%; reported value increased 35.00%, and weight changed +0.37 pp. Weight depends on both the security valuation and total portfolio value, not trade proceeds.SEC filing ↗
Filed Feb 11, 2025
Q1 20251.68%2,077,173$37.22MShares decreased 2.28%; reported value increased 0.52%, and weight changed +0.25 pp. Weight depends on both the security valuation and total portfolio value, not trade proceeds.SEC filing ↗
Filed May 1, 2025
Q2 20251.13%2,091,360$30.95MShares increased 0.68%; reported value decreased 16.85%, and weight changed -0.55 pp. Weight depends on both the security valuation and total portfolio value, not trade proceeds.SEC filing ↗
Filed Aug 4, 2025
Q3 20251.64%2,146,767$51.31MShares increased 2.65%; reported value increased 65.76%, and weight changed +0.51 pp. Weight depends on both the security valuation and total portfolio value, not trade proceeds.SEC filing ↗
Filed Oct 30, 2025
Q4 20251.88%1,594,184$60.91MShares decreased 25.74%; reported value increased 18.72%, and weight changed +0.24 pp. Weight depends on both the security valuation and total portfolio value, not trade proceeds.SEC filing ↗
Filed Feb 9, 2026
Q1 20261.46%1,557,196$46.26MShares decreased 2.32%; reported value decreased 24.05%, and weight changed -0.42 pp. Weight depends on both the security valuation and total portfolio value, not trade proceeds.SEC filing ↗
Filed May 4, 2026
Q2 20262.14%1,600,886$90.95MShares increased 2.81%; reported value increased 96.58%, and weight changed +0.68 pp. Weight depends on both the security valuation and total portfolio value, not trade proceeds.SEC filing ↗
Filed Aug 5, 2026
EMERALD ADVISERS, LLC · TRAVERE THERAPEUTICS INC

Take these holdings further.

This page includes 12 of 12 reported holdings. Sign in to look up the full history beyond 3 years, use advanced screening & filtering, download CSV, and get the complete set through the Akkru API.

  • Download CSV
  • Earlier quarters
  • Advanced screening & filtering
  • API & AI access
Already have an account?

+ New accounts get free API credits to explore data beyond ownership filings.

For AI agents & developers

The initial HTML of this page carries its exact data as script#research-data (JSON): values, units, scope, preview limits and SEC sources. Read it directly, no script or API key needed; script#research-access says what needs an account.

Without an account: the last 3 years, with the row caps stated on the page. A free account opens all history on file on these pages and the CSV of what a page shows. Rows beyond the caps and bulk retrieval go through the authenticated API / MCP.

MCP  https://api.akkrudata.ai/mcp

get_institutional_portfolio
{"cik":"1015083","quarter":"2026Q2","cusip":"89422G107"}

get_institutional_manager_history
{"cik":"1015083","page_size":100}

Connect to MCP with OAuth and follow the returned pagination. Credits and usage limits depend on the account.

MCP endpoint
https://api.akkrudata.ai/mcp
API / MCP documentation
/documents
llms.txt
/llms.txt
Sources, coverage & how to read this data

Figures are as reported to the SEC and merged with later amendments where Akkru could match them. Preview limits apply to what is listed, not to the totals, which come from the complete reported data. Nothing is zero-filled: a missing quarter or month is shown as missing.

13F reports quarter-end long positions in securities traded on US exchanges, filed by managers holding at least $100 million of such securities; it is not the manager's full portfolio, not assets under management, and value changes are not returns. Weights use the reported total value as denominator. Option rows show notional value, not premium or net exposure. Amendments are merged into the quarter when Akkru could match them.